HT
PTGX icon

HAP Trading’s Protagonist Therapeutics PTGX Stock Holding History

HAP Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,166
Closed -$655K – 2658
2021
Q4 		$655K Sell
19,166
-1,743
-8% -$55.1K 0.02% 598
2021
Q3 		$371K Buy
+20,909
New +$891K 0.01% 777

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HAP Trading's PTGX Position: Q1 2022 in Review

HAP Trading sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 19,166 shares — an estimated $655K sold.

HAP Trading first reported a position in PTGX in Q3 2021 and held it in 2 quarters. The position peaked at $655K in Q4 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

  • HAP Trading reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
  • HAP Trading sold 19,166 Protagonist Therapeutics shares in Q1 2022, an estimated $655K.
  • HAP Trading first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 2 quarters.
  • HAP Trading's Protagonist Therapeutics position peaked at $655K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on HAP Trading's 13F filing for Q1 2022, filed 12 May 2022.